NGX-4010 for the Treatment of Postherpetic Neuralgia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

Not specified

Conditions
Herpes ZosterNeuralgiaPainPeripheral Nervous System DiseasesShingles
Interventions
DRUG

Capsaicin Dermal Patch

Trial Locations (28)

12205

NeurogesX Investigational Site, Albany

14642

NeurogesX Investigational Site, Rochester

32935

NeurogesX Investigational Site, Melbourne

33324

NeurogesX Investigational Site, Plantation

33410

NeurogesX Investigational Site, Palm Beach Garden

33702

NeurogesX Investigational Site, St. Petersburg

34102

NeurogesX Investigational Site, Naples

34232

NeurogesX Investigational Site, Sarasota

34471

NeurogesX Investigational Site, Ocala

35801

NeurogesX Investigational Site, Huntsville

64132

NeurogesX Investigational Site, Kansas City

72205

NeurogesX Investigational Site, Little Rock

75234

NeurogesX Investigational Site, Dallas

78229

NeurogesX Investigational Site, San Antonio

78758

NeurogesX Investigational Site, Austin

80218

NeurogesX Investigational Site, Denver

84107

NeurogesX Investigational Site, Salt Lake City

85023

NeurogesX Investigational Site, Phoenix

85724

NeurogesX Investigational Site, Tucson

89102

NeurogesX Investigational Site, Las Vegas

92037

NeurogesX Investigational Site, La Jolla

93104

NeurogesX Investigational Site, Memphis

94117

NeurogesX Investigational Site, San Francisco

97401

NeurogesX Investigational Site, Eugene

98405

NeurogesX Investigational Site, Tacoma

Unknown

NeurogesX Investigational Site, Scottsdale

02115

NeurogesX Investigational Site, Boston

07960

NeurogesX Investigational Site, Morristown

Sponsors

Lead Sponsor

All Listed Sponsors
lead

NeurogesX

INDUSTRY

NCT00061776 - NGX-4010 for the Treatment of Postherpetic Neuralgia | Biotech Hunter | Biotech Hunter